Developing immuno-oncology therapeutics to fight cancer
Pascal Biosciences Inc. (TSX-V: PAS) is a biotechnology company focused on harnessing the body’s immune system to fight cancer. Our mission is to discover and develop innovative therapeutics that empower the immune system to help patients suffering from life-threatening diseases.
Our Pipeline and Research
Pascal Biosciences is currently advancing three programs...
Anti-VpreB Antibody for Leukemia
Restoration of Immune Surveillance
Calcium Channel Antibody
Pascal Biosciences Provides Year-End Investor Update and Reviews Upcoming Milestones MORE >
Pascal Biosciences Announces Year-End Investor Update Webcast - Monday, December 17th at 1:30PM PST MORE >
Pascal Biosciences Expands Leadership Team to Support Strategic Advancement of Its Cannabinoid Based Programs MORE >
Pascal Biosciences Announces Optimization of Cannabinoid-Derived Drug Candidates to Kill Glioblastoma Cells MORE >
Pascal Biosciences and the University of Washington Enter Into Exclusive License Agreement to Develop Cannabinoid-based Medicine for Cancer MORE >
Pascal Biosciences appoints Julie M. Eastland, accomplished financial executive, to Board of Directors MORE >
Pascal Biosciences Receives DEA Schedule I License for Cannabinoid Development and Renews UBC Collaboration MORE >
Pascal Biosciences Identifies Molecules in Cannabis That Stimulate the Immune System to Destroy Tumor Cells MORE >